Literature DB >> 26319607

Clinical and molecular complexity of breast cancer metastases.

Siker Kimbung1, Niklas Loman2, Ingrid Hedenfalk3.   

Abstract

Clinical oncology is advancing toward a more personalized treatment orientation, making the need to understand the biology of metastasis increasingly acute. Dissecting the complex molecular, genetic and clinical phenotypes underlying the processes involved in the development of metastatic disease, which remains the principal cause of cancer-related deaths, could lead to the identification of more effective prognostication and targeted approaches to prevent and treat metastases. The past decade has witnessed significant progress in the field of cancer metastasis research. Clinical and technological milestones have been reached which have tremendously enriched our understanding of the complex pathways undertaken by primary tumors to progress into lethal metastases and how some of these processes might be amenable to therapy. The aim of this review article is to highlight the recent advances toward unraveling the clinical and molecular complexity of breast cancer metastases. We focus on genes mediating breast cancer metastases and organ-specific tropism, and discuss gene signatures for prediction of metastatic disease. The challenges of translating this information into clinically applicable tools for improving the prognostication of the metastatic potential of a primary breast tumor, as well as for therapeutic interventions against latent and active metastatic disease are addressed.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Breast cancer; Metastasis; Organ-specific tropism; Prognosis; Targeted therapy; Tumor heterogeneity

Mesh:

Substances:

Year:  2015        PMID: 26319607     DOI: 10.1016/j.semcancer.2015.08.009

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  50 in total

1.  An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.

Authors:  Yuefeng Yang; Weidong Xu; Di Peng; Hao Wang; Xiaoyan Zhang; Hua Wang; Fengjun Xiao; Yitan Zhu; Yuan Ji; Kamalakar Gulukota; Donald L Helseth; Kathy A Mangold; Megan Sullivan; Karen Kaul; Edward Wang; Bellur S Prabhakar; Jinnan Li; Xuejie Wu; Lisheng Wang; Prem Seth
Journal:  Hum Gene Ther       Date:  2019-07-01       Impact factor: 5.695

2.  Expression of Stanniocalcin 2 in Breast Cancer and Its Clinical Significance.

Authors:  Shu-Ting Jiang; Hua-Qiao Wang; Tie-Cheng Yang; Dan-Wen Wang; Li-Jie Yang; Yi-Qing Xi; Fan-Zheng Kong; Xue-Kai Pan; Li-Hua Xu; Mao-Hui Feng; Wei Xie; Fei Su
Journal:  Curr Med Sci       Date:  2019-12-16

3.  Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer.

Authors:  Stephanie Metcalf; Susan Dougherty; Traci Kruer; Nazarul Hasan; Rumeysa Biyik-Sit; Lindsey Reynolds; Brian F Clem
Journal:  Clin Exp Metastasis       Date:  2019-10-19       Impact factor: 5.150

4.  Breast carcinoma subtypes show different patterns of metastatic behavior.

Authors:  István Artúr Molnár; Béla Ákos Molnár; Laura Vízkeleti; Krisztina Fekete; Judit Tamás; Péter Deák; Csilla Szundi; Borbála Székely; Judit Moldvay; Stefan Vári-Kakas; Marcell A Szász; Balázs Ács; Janina Kulka; Anna-Mária Tőkés
Journal:  Virchows Arch       Date:  2017-01-19       Impact factor: 4.064

5.  DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.

Authors:  Chao-Chieh Lin; Wen-Hsuan Yang; Yi-Tzu Lin; Xiaohu Tang; Po-Han Chen; Chien-Kuang Cornelia Ding; Dan Chen Qu; James V Alvarez; Jen-Tsan Chi
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

Review 6.  Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).

Authors:  Aiswarya Chaudhuri; Dulla Naveen Kumar; Deepa Dehari; Sanjay Singh; Pradeep Kumar; Pradeep Kumar Bolla; Dinesh Kumar; Ashish Kumar Agrawal
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

7.  LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.

Authors:  Weidong Xu; Yuefeng Yang; Zebin Hu; Maria Head; Kathy A Mangold; Megan Sullivan; Edward Wang; Poornima Saha; Kamalakar Gulukota; Donald L Helseth; Theresa Guise; Bellur S Prabhkar; Karen Kaul; Hans Schreiber; Prem Seth
Journal:  Hum Gene Ther       Date:  2020-06-12       Impact factor: 5.695

8.  Blood cadmium levels associated with short distant metastasis-free survival time in invasive breast cancer.

Authors:  Yuanfang He; Lin Peng; Yanhong Huang; Caixia Liu; Shukai Zheng; Kusheng Wu
Journal:  Environ Sci Pollut Res Int       Date:  2017-10-09       Impact factor: 4.223

9.  RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence.

Authors:  James V Alvarez; Jen-Tsan Chi; Chao-Chieh Lin; Nathaniel W Mabe; Yi-Tzu Lin; Wen-Hsuan Yang; Xiaohu Tang; Lisa Hong; Tianai Sun; Jeremy Force; Jeffrey R Marks; Tso-Pang Yao
Journal:  Cell Death Differ       Date:  2020-01-27       Impact factor: 15.828

10.  Extracellular Vesicles Carry lncRNA SNHG16 to Promote Metastasis of Breast Cancer Cells via the miR-892b/PPAPDC1A Axis.

Authors:  Wenfei Xia; Yun Liu; Teng Cheng; Tao Xu; Menglu Dong; Xiaopeng Hu
Journal:  Front Cell Dev Biol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.